FIBROGEN INC - COMMON STOCK

FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics

08 май 2023 15:00:00 Источник Nasdaq GlobeNewswire

FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS)

05 май 2023 06:30:00 Источник Nasdaq GlobeNewswire

FibroGen Announces Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value

01 май 2023 06:00:00 Источник Nasdaq GlobeNewswire

FibroGen to Report First Quarter 2023 Financial Results

24 апр 2023 06:00:00 Источник Nasdaq GlobeNewswire

FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis

03 апр 2023 06:00:00 Источник Nasdaq GlobeNewswire

FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results

27 фев 2023 15:01:00 Источник Nasdaq GlobeNewswire

FibroGen to Present at Cowen’s 43rd Annual Health Care Conference

27 фев 2023 06:00:00 Источник Nasdaq GlobeNewswire

FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results

17 фев 2023 06:00:00 Источник Nasdaq GlobeNewswire

FibroGen to Present at SVB Securities Global Biopharma Conference

02 фев 2023 06:00:00 Источник Nasdaq GlobeNewswire

FibroGen to Participate at Bank of America 2022 Biotech SMID Cap Virtual Conference

28 ноя 2022 06:00:00 Источник Nasdaq GlobeNewswire

FibroGen Reports Third Quarter 2022 Financial Results

07 ноя 2022 15:01:00 Источник Nasdaq GlobeNewswire

FibroGen Announces $50 Million Royalty Monetization Financing with NovaQuest Capital Management

07 ноя 2022 15:00:00 Источник Nasdaq GlobeNewswire

FibroGen to Participate at Stifel 2022 Healthcare Conference

01 ноя 2022 06:00:01 Источник Nasdaq GlobeNewswire

FibroGen to Report Third Quarter 2022 Financial Results

24 окт 2022 06:00:00 Источник Nasdaq GlobeNewswire

FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic Syndromes (MDS)

26 авг 2022 06:00:00 Источник Nasdaq GlobeNewswire

FibroGen Reports Second Quarter 2022 Financial Results

08 авг 2022 15:01:00 Источник Nasdaq GlobeNewswire

FibroGen to Report Second Quarter 2022 Financial Results

25 июл 2022 06:00:33 Источник Nasdaq GlobeNewswire

FibroGen to Participate at William Blair Biotech Focus Conference 2022

01 июл 2022 06:00:00 Источник Nasdaq GlobeNewswire

FibroGen Announces Completion of Patient Enrollment in LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Duchenne Muscular Dystrophy

08 июн 2022 06:00:01 Источник Nasdaq GlobeNewswire

FibroGen to Present at Jefferies Healthcare Conference

26 май 2022 06:00:00 Источник Nasdaq GlobeNewswire